JP2024524222A5 - - Google Patents

Info

Publication number
JP2024524222A5
JP2024524222A5 JP2023578940A JP2023578940A JP2024524222A5 JP 2024524222 A5 JP2024524222 A5 JP 2024524222A5 JP 2023578940 A JP2023578940 A JP 2023578940A JP 2023578940 A JP2023578940 A JP 2023578940A JP 2024524222 A5 JP2024524222 A5 JP 2024524222A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
nucleoside
complex according
seq
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/033956 external-priority patent/WO2022271543A2/en
Publication of JP2024524222A publication Critical patent/JP2024524222A/ja
Publication of JP2024524222A5 publication Critical patent/JP2024524222A5/ja
Pending legal-status Critical Current

Links

JP2023578940A 2021-06-21 2022-06-17 筋標的化複合体およびフリードライヒ運動失調症を処置するためのその使用 Pending JP2024524222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163212816P 2021-06-21 2021-06-21
US63/212,816 2021-06-21
PCT/US2022/033956 WO2022271543A2 (en) 2021-06-21 2022-06-17 Muscle targeting complexes and uses thereof for treating friedreich's ataxia

Publications (2)

Publication Number Publication Date
JP2024524222A JP2024524222A (ja) 2024-07-05
JP2024524222A5 true JP2024524222A5 (cg-RX-API-DMAC7.html) 2025-06-25

Family

ID=84545809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578940A Pending JP2024524222A (ja) 2021-06-21 2022-06-17 筋標的化複合体およびフリードライヒ運動失調症を処置するためのその使用

Country Status (6)

Country Link
US (1) US20250099603A9 (cg-RX-API-DMAC7.html)
EP (1) EP4359008A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024524222A (cg-RX-API-DMAC7.html)
CN (1) CN118251238A (cg-RX-API-DMAC7.html)
CA (1) CA3222816A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022271543A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517877B2 (en) * 2016-03-30 2019-12-31 Wisconsin Alumni Research Foundation Compounds and methods for modulating frataxin expression
WO2019126641A2 (en) * 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
AU2019315593B2 (en) * 2018-08-02 2026-05-21 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
CA3108386A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating friedreich's ataxia
CN114025805B (zh) * 2019-06-07 2025-01-24 达因疗法公司 制备蛋白质-寡核苷酸复合物的方法
CN115427448A (zh) * 2020-01-10 2022-12-02 达因疗法公司 肌肉靶向复合物及其用途
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof

Similar Documents

Publication Publication Date Title
JP2023535078A5 (cg-RX-API-DMAC7.html)
JP2024503609A5 (cg-RX-API-DMAC7.html)
JP2023509793A5 (cg-RX-API-DMAC7.html)
JP2023512441A5 (cg-RX-API-DMAC7.html)
IL309910A (en) Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
JP2023510350A5 (cg-RX-API-DMAC7.html)
JP7447073B2 (ja) Pd-l1発現低減用のオリゴヌクレオチド
JP2024160045A5 (cg-RX-API-DMAC7.html)
JP2024527362A5 (cg-RX-API-DMAC7.html)
JP2024501872A5 (cg-RX-API-DMAC7.html)
JP2023535073A5 (cg-RX-API-DMAC7.html)
JP2024546436A5 (cg-RX-API-DMAC7.html)
JP2024525611A5 (cg-RX-API-DMAC7.html)
IL309936A (en) Muscle targeting complexes and formulations for treating dystrophinopathies
JP2024525610A5 (cg-RX-API-DMAC7.html)
IL316143A (en) Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
JP2021533197A5 (cg-RX-API-DMAC7.html)
JP2025512469A5 (cg-RX-API-DMAC7.html)
JP2023510351A5 (cg-RX-API-DMAC7.html)
JP2024525613A5 (cg-RX-API-DMAC7.html)
JP2021533199A5 (cg-RX-API-DMAC7.html)
JP2023512442A5 (cg-RX-API-DMAC7.html)
JP2024525612A5 (cg-RX-API-DMAC7.html)
JP2024525614A5 (cg-RX-API-DMAC7.html)
JP2025512468A5 (cg-RX-API-DMAC7.html)